Methodological considerations for research in geriatric clinical pharmacology that have pertinence for Phase 1 and 2 drug testing in elderly subjects and patients are discussed. Such considerations include study design, subject recruitment, feasibility, data analysis, and reporting.
KleinCEGermanPSLevineDM: Adverse drug reactions among the elderly: A reassessment. J Am Geriatr Soc1981;29:525–530.
2.
VestalREJueSGCusackBJ: Increased risk of adverse drug reactions in the elderly: Fact or myth? in: O'MalleyKWaddingtonJL (eds): Therapeutics in the Elderly. Amsterdam, Elsevier Science Publishers, 1985, pp 97–104.
3.
SmithMcFate W: Resources in geriatric drug research. Drug Inf J1985;19:421–427.
4.
RoweJW: Clinical research on aging: Strategies and directions. N Engl J Med1977;297:1332–1336.
5.
VestalRE: Methodological problems associated with studies of drug metabolism in the elderly, in TurnerP (ed): Clinical Pharmacology and Therapeutics: Proceedings of the First World Conference. London, Macmillan Publishers Ltd, 1980, pp 108–116.
6.
ShockNWGreulichRCAndresR: Normal Human Aging: The Baltimore Longitudinal Study of Aging. National Institutes of Health publication No. 842450, Government Printing Office, 1984.
7.
VestalREDawsonGW: Pharmacology and aging, in FinchCESchneiderEL (eds): Handbook of the Biology of Aging, ed 2. New York, Van Nostrand, 1985, pp 744–819.
8.
GreenblattDJSellersEMShaderRI: Drug disposition in old age. N Engl J Med1982;306: 1081–1088.
9.
VestalREWoodAJJ: Influence of age and smoking on drug kinetics in man: Studies using model compounds. Clin Pharmacokinet1980;5:309–319.
10.
DoyleVO'MalleyKKellyJG: Human lymphocytes β-adrenoceptor density in relation to age and hypertension. J Cardiovasc Pharmacol1982;4: 738–740.
11.
McGuireEAHHeldermanJRTobinJD: Effects of arterial versus venous sampling on analysis of glucose kinetics in man. J Appl Physiol1976;41:565–573.
12.
SaundersNAPowlesACPRebuckAS: Ear oximetry: Accuracy and practicability in the assessment of arterial oxygenation. Am Rev Respir Dis1976;113:745–749.
13.
CastledenCMKayneCMParsonsRL: The effect of age on plasma levels of propranolol and practolol in man. Br J Clin Pharmacol1975;2: 303–306.
14.
CastledenCMGeorgeCF: The effect of aging on the hepatic clearance of propranolol. Br J Clin Pharmacol1979;7:49–54.
15.
VestalREWoodAJJBranchRA: Effects of age and cigarette smoking on propranolol disposition. Clin Pharmacol Ther1979;26:8–15.
16.
WalleTConradiECWalleUK: The predictable relationship between plasma levels and dose during chronic propranolol therapy. Clin Pharmacol Ther1978;24:668–677.
17.
SchneckDWLudererJRPritchardJF: A comparison of the intrinsic clearance of propranolol in young and elderly subjects. Clin Pharmacol Ther1980;27:284–285.
18.
CusackBJDawsonGWMercerG: Theophylline metabolism but not the inhibitory effect of cimetidine is impaired in the elderly. Clin Res1984;32:240A.
19.
RoweJWAndresRTobinJD: The effect of age on creatinine clearance in man: A cross-sectional and longitudinal study. J Gerontol1976;31:155–163.
20.
VestalRENorrisAHTobinJD: Antipyrine metabolism in man: Influence of age, alcohol, caffeine, and smoking. Clin Pharmacol Ther1975;18:425–432.
21.
SmithardDJLangmanMJS: The effect of vitamin supplementation upon antipyrine metabolism in the elderly. Br J Clin Pharmacol1978;5:181–185.
22.
SwiftCGHomeidaMHalliwellM: Antipyrine disposition and liver size in the elderly. Eur J Clin Pharmacol1978;14:149–152.
23.
MillerAKAdirJVestalRE: Effect of age on the pharmacokinetics of tolbutamide in man. Pharmacologist1977;19:128.
24.
SwerdloffRSPozefskyTTobinJD: Influence of age on the intravenous tolbutamide response test. Diabetes1967;16:161–170.
25.
SnedecorGWCochranWG: Statistical Methods, ed 6. Ames, Iowa, Iowa State University Press, 1967.
